Beam Therapeutics Inc. (BEAM)

Market Cap	1.82B
Revenue (ttm)	80.16M
Net Income (ttm)	-327.16M
Shares Out	79.20M
EPS (ttm)	-4.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	299
Open	23.62
Previous Close	23.76
Day's Range	22.52 - 23.62
52-Week Range	22.52 - 54.30
Beta	1.56
Analysts	Buy
Price Target	57.89 (+151.59%)
Earnings Date	Nov 6, 2023

About BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting L...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 6, 2020
• Employees: 532
• Stock Exchange: NASDAQ
• Ticker Symbol: BEAM

Financial Performance

In 2022, BEAM's revenue was $60.92 million, an increase of 17.51% compared to the previous year's $51.84 million. Losses were -$289.09 million, -22.00% less than in 2021.

Analyst Forecast

According to 9 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is $57.89, which is an increase of 151.59% from the latest price.

Price Target

$57.89

(151.59% upside)

Analyst Consensus: Buy